Development and Clinical Performance of InteliSwab ® COVID-19 Rapid Test: Evaluation of Antigen Test for the Diagnosis of SARS-CoV-2 and Analytical Sensitivity to Detect Variants of Concern Including Omicron and Subvariants.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: MDPI Country of Publication: Switzerland NLM ID: 101509722 Publication Model: Electronic Cited Medium: Internet ISSN: 1999-4915 (Electronic) Linking ISSN: 19994915 NLM ISO Abbreviation: Viruses Subsets: MEDLINE
    • Publication Information:
      Original Publication: Basel, Switzerland : MDPI
    • Subject Terms:
      SARS-CoV-2*/genetics ; COVID-19*/diagnosis; Humans ; Biological Assay ; Blotting, Western ; COVID-19 Testing
    • Abstract:
      Background and Objectives: Timely detection of SARS-CoV-2 infection with subsequent contact tracing and rapid isolation are considered critical to containing the pandemic, which continues with the emergence of new variants. Hence, there is an ongoing need for reliable point-of-care antigen rapid diagnostic tests (Ag-RDT). This report describes the development, evaluation, and analytical sensitivity of the diagnostic performance of the InteliSwab ® COVID-19 Rapid Test. Methods : Samples from 165 symptomatic subjects were tested with InteliSwab ® and the results were compared to RT-PCR to determine the antigen test performance. The analytical sensitivity of InteliSwab ® for the detection of different variants was assessed by limit of detection (LOD) determination using recombinant nucleocapsid proteins (NPs) and testing with virus isolates. Western immunoblot independently confirmed that each monoclonal Ab is capable of binding to all variants tested thus far.
      Results: The overall positivity rate by RT-PCR was 37% for the 165 symptomatic subjects. Based on RT-PCR results as the reference standard, InteliSwab ® showed clinical sensitivity and specificity of 85.2% (95% CI, 74.3-92.0%) and 98.1% (95% CI, 93.3-99.7%), respectively. The overall agreement was 93.3% (Kappa index value 0.85; 95% CI, 0.77-0.74) between RT-PCR and InteliSwab ® test results. Furthermore, the evaluation of analytical sensitivity for different SARS-CoV-2 variants by InteliSwab ® was comparable in the detection of all the variants tested, including Omicron subvariants, BA.4, BA.5, and BQ.1.
      Conclusions: Due to the surge of infections caused by different variants from time to time, there is a critical need to evaluate the sensitivity of rapid antigen-detecting tests for new variants. The study findings showed the robust diagnostic performance of InteliSwab ® and analytical sensitivity in detecting different SARS-CoV-2 variants, including the Omicron subvariants. With the integrated swab and excellent sensitivity and variant detection, this test has high potential as a point-of-care Ag-RDT in various settings when molecular assays are in limited supply and rapid diagnosis of SARS-CoV-2 is necessary.
    • References:
      MAbs. 2010 Jan-Feb;2(1):53-66. (PMID: 20168090)
      Cochrane Database Syst Rev. 2021 Mar 24;3:CD013705. (PMID: 33760236)
      J Clin Microbiol. 2021 Apr 20;59(5):. (PMID: 33318065)
      Clin Microbiol Infect. 2021 Mar;27(3):472.e7-472.e10. (PMID: 33189872)
      Lancet Public Health. 2020 Aug;5(8):e452-e459. (PMID: 32682487)
      N Engl J Med. 2020 Nov 26;383(22):e120. (PMID: 32997903)
      Microbiol Spectr. 2022 Jun 29;10(3):e0102522. (PMID: 35616382)
      J Clin Virol. 2020 Dec;133:104684. (PMID: 33176236)
      Biometrics. 1977 Mar;33(1):159-74. (PMID: 843571)
      Lab Med. 2020 Sep 1;51(5):e59-e65. (PMID: 32657343)
      Ann Intern Med. 2023 Jul;176(7):975-982. (PMID: 37399548)
      Lancet Glob Health. 2020 Apr;8(4):e488-e496. (PMID: 32119825)
      Diagnostics (Basel). 2022 Feb 12;12(2):. (PMID: 35204566)
      J Virol Methods. 2004 Sep 1;120(1):87-96. (PMID: 15234813)
      Viruses. 2022 Mar 06;14(3):. (PMID: 35336950)
      Clin Microbiol Infect. 2021 Apr;27(4):636.e1-636.e4. (PMID: 33421573)
      Infect Immun. 1994 May;62(5):1576-83. (PMID: 7513303)
      Vacunas. 2022 Jan-Apr;23(1):55-61. (PMID: 34276268)
      J Gene Med. 2021 Feb;23(2):e3303. (PMID: 33305456)
      BMJ. 2015 Oct 28;351:h5527. (PMID: 26511519)
    • Grant Information:
      EUA; 75A50120C00061 and 510(k); 75A50121C00078 Biomedical Advanced Research and Development Authority
    • Contributed Indexing:
      Keywords: COVID-19; Omicron; SARS-CoV-2; diagnosis; rapid antigen test; variants of concern
    • Subject Terms:
      SARS-CoV-2 variants
    • Publication Date:
      Date Created: 20240123 Date Completed: 20240124 Latest Revision: 20241023
    • Publication Date:
      20241023
    • Accession Number:
      PMC10821026
    • Accession Number:
      10.3390/v16010061
    • Accession Number:
      38257761